TRVN Profile
Trevena, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapeutics targeting central nervous system disorders. The company's portfolio includes several advanced product candidates designed to address significant unmet medical needs. Trevena's lead product, OLINVYK (Oliceridine), is a G protein-biased mu-opioid receptor (MOR) ligand formulated as an injectable treatment for managing moderate-to-severe acute pain. OLINVYK aims to provide effective pain relief with potentially reduced side effects compared to traditional opioids.
In addition to OLINVYK, Trevena is advancing several other promising candidates. TRV027 is being developed for the treatment of acute lung injury and associated conditions, including acute respiratory distress syndrome (ARDS) and abnormal blood clotting in COVID-19 patients. TRV250 is a G protein-biased delta-opioid receptor agonist under investigation for its efficacy in treating acute migraine. TRV734, a small molecule G protein-biased ligand of the MOR, is aimed at addressing moderate-to-severe acute and chronic pain, offering an alternative to conventional pain management options. Lastly, TRV045 is a novel sphingosine-1-phosphate (S1P) modulator in development for chronic pain management.
Trevena's research and development efforts are supported by strategic collaborations, including a partnership with Imperial College London to evaluate TRV027 in COVID-19 patients. This collaboration underscores the company's commitment to leveraging cutting-edge science and academic expertise to advance its therapeutic programs. The company's focus on central nervous system disorders reflects its dedication to addressing complex and often challenging medical conditions with novel treatment approaches.
Established in 2007 and headquartered in Chesterbrook, Pennsylvania, Trevena, Inc. benefits from a robust pipeline of drug candidates and a strong commitment to innovation in biopharmaceutical research. The company continues to build on its scientific expertise and strategic alliances to drive the development of its product candidates and deliver new treatment options to patients in need.
|
